Humoral Response to SARS-CoV-2 Vaccine-Boost in Cancer Patients: A Case Series from a Southern European Cancer Center
In conclusion, cancer patients have a weaker immune response to the SARS-CoV-2 vaccine, especially those with hematological cancers. Chemotherapy and febrile neutropenia risk further reduce booster effectiveness. Further research is needed to optimize vaccine timing for cancer patients undergoing chemotherapy.
Authors
- Mário Sousa‐Pimenta
- Bruno Ferreira Soares
- Rui Medeiros (ORCID: https://orcid.org/0000-0003-3010-8373)
- Francisca Dias (ORCID: https://orcid.org/0000-0002-4993-4467)
- Júlio Oliveira (ORCID: https://orcid.org/0000-0002-9576-3486)
- Rui Manuel Pinto Costa (ORCID: https://orcid.org/0000-0001-7040-3487)
- Beatriz Almeida (ORCID: https://orcid.org/0000-0002-1674-3576)
- Tânia R. Dias (ORCID: https://orcid.org/0000-0002-2336-8006)
- Hugo Sousa (ORCID: https://orcid.org/0000-0001-5795-2131)
- Carlos Ochoa (ORCID: https://orcid.org/0000-0003-0489-9677)
- Pedro Cruz (ORCID: https://orcid.org/0000-0001-8813-0632)
Institutions
- Fernando Pessoa University (PT)
- Universidade do Porto (PT)
- Portuguese League Against Epilepsy (PT)
- Instituto Português de Oncologia Francisco Gentil (PT)
- IPO Porto (PT)
Publication Details
- Journal
- Vaccines
- Published
- 2024-10-24
- DOI
- https://doi.org/10.3390/vaccines12111207
- Citations
- 3
- Primary Topic
- Chemotherapy-related skin toxicity
- Type
- article
- Field-Weighted Citation Impact
- 1.60
Funders
- Liga Portuguesa Contra o Cancro